Catalent (CTLT) delivered earnings and revenue surprises of -125% and 3.10%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
SOMERSET, N.J., May 08, 2024--Catalent, Inc. (NYSE: CTLT) ("Catalent"), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the third quarter of fiscal 2024, which ended March 31, 2024.
Catalent said on Friday the companies were in the process of gathering information to respond to the U.S. Federal Trade Commission's request received on May 2. Novo Holdings in February agreed to buy Catalent to boost output of the popular weight-loss drug Wegovy.